Concurrent chemotherapy, proton therapy improves survival in patients with advanced lung cancer
For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy, offers improved survival compared to historical data for standard of care, according to a new study from The University of Texas MD Anderson Cancer Center.
The research, published in JAMA Oncology, reported an overall survival (OS) of 26.5 months. In contrast, the historical OS rate with standard...
Genetically enhanced, cord-blood derived immune cells strike B-cell cancers
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down...
Tumor-targeting drug shows potential for treating bone cancer patients
The treatment of osteosarcoma, the most common tumor of bone, is challenging. A study led by The University of Texas MD Anderson Cancer Center...
Recommendation for the further treatment of Chinese Nobel Prize Laureate Liu Xiaobo
Joint Statement from Dr. Joseph M. Herman, Clinical Research Director, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, and Dr. Markus Büchler, Chairman, Department of Surgery, University of Heidelberg
On Saturday, July 8, Dr. Joseph M. Herman of The University of Texas MD Anderson Cancer Center and Dr. Markus W Büchler of University of Heidelberg met with the medical team at the No. 1 Hospital...